EBR Systems (ASX:EBR) said the US Food and Drug Administration (FDA) started its pre-approval inspection of the company's new manufacturing facility in Santa Clara, California, marking a key step in the regulatory process, according to a Tuesday filing with the Australian bourse.
The company still anticipates receiving US FDA approval for the facility by the end of the year, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.